Reference images only. Packaging and labels vary by country and batch. Always consult the leaflet supplied with your product.
Available in:
🇨🇿🇩🇪🇬🇧🇯🇵🇵🇱🇵🇹🇸🇰🇹🇷
Form
Tabletki powlekane
Dosage
20 mg
Route
—
Storage
—
About This Product
Manufacturer
Gruenenthal GmbH
ATC Code
C10AA07
Source
URPL
11 DESCRIPTION Rosuvastatin calcium is a synthetic lipid-lowering agent for oral administration. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula: The empirical formula for rosuvastatin calcium is (C 22 H 27 FN 3 O 6 S) 2 Ca and the molecular weight is 1001.14. Rosuvastatin calcium, USP is a white amorphous powder that is sparingly soluble in water and methanol, and slightly soluble in ethanol. Rosuvastatin calcium, USP is a hydrophilic compound with a partition coefficient (octanol/water) of 0.13 at pH of 7.0. Rosuvastatin tablets, USP for oral administration contain 5, 10, 20, or 40 mg of rosuvastatin and the following inactive ingredients: For 5 mg: Each film coated tablet contains: microcrystalline cellulose, lactose monohydrate, anhydrous lactose, crospovidone, magnesium oxide, magnesium stearate, hypromellose, triacetin, titanium dioxide, and ferric oxide yellow. For 10, 20 and 40 mg: Each film coated tablet contains: microcrystalline cellulose, lactose monohydrate, anhydrous lactose, crospovidone, magnesium oxide, magnesium stearate, hypromellose, triacetin, titanium dioxide, FD & C yellow No. 6, FD & C red No. 40, and FD & C blue No.1. Rosuvastatin tablets, USP meet USP Dissolution Test 2.
⚠️ Warnings
• Not to be used in patient with acute, serious condition suggestive of muscular diseases(myopathy) or predisposing to the development of kidney failure secondary to rapid breakdown of skeletal muscle(rhabdomyolysis) e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders or uncontrolled seizures.
Caution should be exercised in patients with history of liver disease and alcoholism.
• Discontinue treatment if there is marked or persistent increase in serum aminotransferase concentrations, significant increase in creatinine phosphokinase or evidence of muscular diseases.
♦
Monitor liver function regularly while taking this medication
.